Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(5).229
O. Ojo
Global diabetes market is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate.
{"title":"2020 Market Analysis","authors":"O. Ojo","doi":"10.37532/1758-1907.2021.11(5).229","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(5).229","url":null,"abstract":"Global diabetes market is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"229"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(7).245-253
D. Folinas, Maria Tzilini Kyriakos Kazakos
The study aims to identify and present the functional and non-functional technical and medical specifications of the software application that supports the clinical care of Diabetes Mellitus (DM) patients and maintain clinical information for monitoring, evaluation, and administration purposes in a research project titled cometech. The proposed software application belongs to the Electronic Health Management Information Systems (eHMIS) category that is designed to fulfill the need for an automated national health information management system. It is used for public health-related decision-making. Its main users are public policymakers, health officers, researchers, planning departments of health offices, eHMIS focal persons, data entry clerks, and many others ranging from health facility to federal management levels. The identification and analysis of the functional and non-functional requirements will help researchers to design and develop similar software applications that aim to introduce telehealth tools and services to achieve continuity of health care and to provide consultation and patient education (society awareness).
{"title":"Identifying functional and non-functional specifications of a telehealth software application for diabetes mellitus","authors":"D. Folinas, Maria Tzilini Kyriakos Kazakos","doi":"10.37532/1758-1907.2021.11(7).245-253","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(7).245-253","url":null,"abstract":"The study aims to identify and present the functional and non-functional technical and medical specifications of the software application that supports the clinical care of Diabetes Mellitus (DM) patients and maintain clinical information for monitoring, evaluation, and administration purposes in a research project titled cometech. The proposed software application belongs to the Electronic Health Management Information Systems (eHMIS) category that is designed to fulfill the need for an automated national health information management system. It is used for public health-related decision-making. Its main users are public policymakers, health officers, researchers, planning departments of health offices, eHMIS focal persons, data entry clerks, and many others ranging from health facility to federal management levels. The identification and analysis of the functional and non-functional requirements will help researchers to design and develop similar software applications that aim to introduce telehealth tools and services to achieve continuity of health care and to provide consultation and patient education (society awareness).","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"245-253"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
——— DOSAGE FORMS AND STRENGTHS ——— Injection: 2 mg/1.5 mL (1.34 mg/mL) available in: • Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection (3). • Single-patient-use pen that delivers 1 mg per injection (3). ——— CONTRAINDICATIONS ——— • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4). • Known hypersensitivity to OZEMPIC® or any of the product components (4). ——— WARNINGS AND PRECAUTIONS ——— • Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). • Never share an OZEMPIC® pen between patients, even if the needle is changed (5.4). • Hypoglycemia: When OZEMPIC® is used with an insulin secretagogue or insulin, consider lowering the dose of the secretagogue or insulin to reduce the risk of hypoglycemia (5.5). • Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions (5.6). • Hypersensitivity Reactions: Discontinue OZEMPIC® if suspected and promptly seek medical advice (5.7). ——— ADVERSE REACTIONS ——— The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-888693-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
{"title":"Oral medications","authors":"Janet Titchener","doi":"10.4324/9780429326196-5","DOIUrl":"https://doi.org/10.4324/9780429326196-5","url":null,"abstract":"——— DOSAGE FORMS AND STRENGTHS ——— Injection: 2 mg/1.5 mL (1.34 mg/mL) available in: • Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection (3). • Single-patient-use pen that delivers 1 mg per injection (3). ——— CONTRAINDICATIONS ——— • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4). • Known hypersensitivity to OZEMPIC® or any of the product components (4). ——— WARNINGS AND PRECAUTIONS ——— • Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). • Never share an OZEMPIC® pen between patients, even if the needle is changed (5.4). • Hypoglycemia: When OZEMPIC® is used with an insulin secretagogue or insulin, consider lowering the dose of the secretagogue or insulin to reduce the risk of hypoglycemia (5.5). • Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions (5.6). • Hypersensitivity Reactions: Discontinue OZEMPIC® if suspected and promptly seek medical advice (5.7). ——— ADVERSE REACTIONS ——— The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-888693-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42854706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：